GO:0035357 peroxisome proliferator activated receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035357 describes a nuclear receptor-mediated signaling pathway that begins with ligand binding to an intracellular peroxisome proliferator activated receptor (PPAR alpha, beta/delta, or gamma) and ends with regulation of downstream cellular processes such as transcription.
• PPAR signaling is central to lipid metabolism, energy homeostasis, and autophagy, and its dysregulation is linked to cancer, metabolic disease, and autoimmune conditions.
• The three PPAR subtypes (alpha, beta/delta, gamma) have distinct tissue distributions and downstream functions, enabling subtype-selective therapeutic targeting.
• PPAR gamma is a well-established target in carcinogenesis and chemoprevention, while PPAR alpha signaling is implicated in hepatocarcinogenesis.
• PPAR beta/delta acts as an acute signaling factor in prostacyclin-induced pulmonary vasodilation and is also linked to reactive oxygen species and redox signaling in cancer.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential tools for dissecting PPAR pathway causality and for developing targeted therapeutics.
Description
The peroxisome proliferator activated receptor (PPAR) signaling pathway, annotated as GO:0035357, is a nuclear receptor-mediated signaling cascade initiated by ligand binding to intracellular PPAR proteins (alpha, beta/delta, or gamma) and culminating in the regulation of downstream cellular processes, most notably transcription. PPARs are ligand-activated transcription factors that sense fatty acids and their derivatives, positioning this pathway as a critical node in lipid metabolism, energy homeostasis, and cellular differentiation. Because PPAR signaling integrates metabolic and inflammatory cues, it has become a major focus in diseases ranging from cancer to autoimmune thyroiditis and pulmonary hypertension. Researchers study GO:0035357 to understand how environmental and endogenous ligands reshape gene expression programs, and to identify druggable targets for therapeutic intervention. The pathway's complexity, involving three subtypes with overlapping and distinct functions, makes it an attractive but challenging subject for functional genomics and CRISPR-based modeling.
peroxisome proliferator activated receptor signaling pathway At A Glance
| GO ID | GO:0035357 |
|---|---|
| GO term | peroxisome proliferator activated receptor signaling pathway |
| Ontology | biological_process |
| Synonym | PPAR signaling pathway; peroxisome proliferator-activated receptor signaling pathway; peroxisome proliferator activated receptor signalling pathway |
| Major function | Ligand-activated nuclear receptor signaling that regulates transcription and downstream cellular processes such as lipid metabolism, energy homeostasis, and autophagy |
| Receptor subtypes | PPAR alpha (NR1C1), PPAR beta/delta (NR1C2), PPAR gamma (NR1C3) |
| Ligand class | Fatty acids, eicosanoids, and synthetic agonists such as fibrates and thiazolidinediones |
| Key downstream process | Regulation of gene transcription via PPAR-RXR heterodimers binding to PPAR response elements |
| Disease relevance | Cancer, metabolic disorders, autoimmune thyroiditis, pulmonary vasodilation defects |
What Is GO:0035357?
GO:0035357 (peroxisome proliferator activated receptor signaling pathway) is defined as a nuclear receptor-mediated signaling pathway that is initiated by a ligand binding to an intracellular peroxisome proliferator activated receptor (alpha, beta, or gamma) of the nuclear receptor protein family, and that ends with regulation of a downstream cellular process, for example transcription. In simpler terms, it is the entire sequence of molecular events from a fatty-acid-like molecule docking onto a PPAR protein inside the cell to changes in gene activity that alter metabolism, growth, or differentiation.
Why Is peroxisome proliferator activated receptor signaling pathway Important in Cell Biology?
GO:0035357 is important because PPAR signaling sits at the intersection of metabolism, inflammation, and cell fate decisions, and its dysfunction is causally implicated in a wide spectrum of human diseases. PPAR alpha signaling has been linked to hepatocarcinogenesis, PPAR gamma to sperm physiology and cancer chemoprevention, and PPAR beta/delta to pulmonary vasodilation and redox signaling in cancer. Moreover, the pathway is a validated drug target: fibrates activate PPAR alpha to lower lipids, and thiazolidinediones activate PPAR gamma to improve insulin sensitivity. Understanding the precise molecular steps of GO:0035357 enables researchers to design subtype-selective modulators and to use CRISPR models to test causality in disease contexts.
• PPAR signaling regulates lipid metabolism and energy homeostasis, making it central to metabolic disease research.
• PPAR gamma activation is a chemopreventive strategy in carcinogenesis, with implications for cancer therapy.
• PPAR alpha signaling is involved in hepatocarcinogenesis, linking the pathway to liver cancer mechanisms.
• PPAR beta/delta mediates acute prostacyclin-induced pulmonary vasodilation, relevant to pulmonary hypertension.
• PPAR signaling interacts with autophagy, a molecular ballet in lipid metabolism and homeostasis.
• The pathway is implicated in autoimmune thyroiditis, as shown by multi-omics analysis of Bailing capsule treatment.
• PPAR gamma signaling influences human sperm physiology, connecting the pathway to reproductive biology.
• PPAR beta/delta, reactive oxygen species, and redox signaling are targets for phytocompound-based cancer therapy.
• The pathway is a validated target for drugs such as fibrates and thiazolidinediones.
• CRISPR-based models enable causal dissection of PPAR pathway genes in disease and development.
What Happens During peroxisome proliferator activated receptor signaling pathway?
Ligand binding and receptor activation
In simple terms: A fat-like molecule enters the cell and attaches to a PPAR protein, switching it on.
The pathway begins when a ligand, such as a fatty acid, eicosanoid, or synthetic agonist, binds to the ligand-binding domain of an intracellular PPAR (alpha, beta/delta, or gamma). This binding induces a conformational change that allows PPAR to release corepressors and recruit coactivators. Ligand specificity and receptor subtype determine which downstream genes are activated, making this step a key point for pharmacological intervention.
Heterodimerization with RXR and DNA binding
In simple terms: The activated PPAR pairs with a partner protein and together they grab onto DNA.
Upon activation, PPAR forms a heterodimer with the retinoid X receptor (RXR). This PPAR-RXR complex binds to specific DNA sequences called PPAR response elements (PPREs) in the regulatory regions of target genes. The heterodimer serves as a transcription factor that directly links ligand availability to gene expression changes.
Transcriptional regulation of target genes
In simple terms: The PPAR-RXR pair turns target genes on or off, changing the cell's behavior.
Once bound to PPREs, the PPAR-RXR heterodimer recruits coactivator complexes that modify chromatin and initiate transcription of target genes involved in lipid transport, beta-oxidation, adipogenesis, and inflammation. PPAR alpha, beta/delta, and gamma regulate overlapping but distinct gene sets, which explains their tissue-specific and context-dependent effects. This transcriptional output constitutes the endpoint of GO:0035357 and drives downstream cellular processes.
Crosstalk with autophagy and metabolic signaling
In simple terms: PPAR signaling talks to the cell's recycling and energy systems to keep balance.
PPAR signaling is tightly interconnected with autophagy, forming a molecular ballet in lipid metabolism and homeostasis. Activation of PPARs can modulate autophagic flux, and in turn, autophagic degradation of lipids (lipophagy) influences PPAR ligand availability. This crosstalk is critical for maintaining energy balance and is dysregulated in metabolic and neoplastic diseases.
Subtype-specific downstream effects
In simple terms: Different PPAR subtypes do different jobs in different tissues.
PPAR alpha is highly expressed in liver and regulates fatty acid oxidation and hepatocarcinogenesis. PPAR gamma is prominent in adipose tissue and immune cells and influences sperm physiology and cancer chemoprevention. PPAR beta/delta acts as an acute signaling factor in pulmonary vasodilation and is linked to reactive oxygen species and redox signaling in cancer. These subtype-specific outputs explain the diverse physiological and pathological roles of GO:0035357.
Key Genes Involved in GO:0035357 peroxisome proliferator activated receptor signaling pathway
The following genes and proteins are core components or well-documented modulators of the peroxisome proliferator activated receptor signaling pathway (GO:0035357).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPARA | Nuclear receptor activated by fatty acids and fibrates; regulates lipid oxidation and hepatocarcinogenesis | Target in metabolic disease and liver cancer; knockout models reveal hepatic lipid handling |
| PPARD | Nuclear receptor mediating acute prostacyclin-induced pulmonary vasodilation and redox signaling | Target in pulmonary hypertension and cancer; point mutants probe ligand selectivity |
| PPARG | Nuclear receptor regulating adipogenesis, sperm physiology, and chemoprevention | Target in diabetes and cancer; knock-in models test synthetic agonists |
| RXRA | Obligate heterodimer partner for PPARs; binds PPREs to activate transcription | Essential for pathway activity; knockout is lethal, conditional models needed |
| RXRB | Alternative RXR partner contributing to PPAR signaling diversity | Modulates subtype-specific transcriptional output |
| NCOA1 | Coactivator recruited by ligand-bound PPAR-RXR to initiate transcription | Overexpression studies enhance PPAR target gene activation |
| NCOA2 | Coactivator that potentiates PPAR-mediated transcription | Knockdown reduces PPAR target gene expression |
| NCOR1 | Corepressor that silences PPAR target genes in the absence of ligand | Knockout leads to constitutive pathway activation |
| NCOR2 | Corepressor contributing to ligand-dependent switching of PPAR activity | Modulates response to PPAR agonists |
| FABP4 | Fatty acid binding protein and PPAR gamma target gene | Marker of adipocyte differentiation and lipid homeostasis |
| CPT1A | Rate-limiting enzyme in fatty acid oxidation and PPAR alpha target | Readout of PPAR alpha activity in liver models |
| ACOX1 | Peroxisomal beta-oxidation enzyme regulated by PPAR alpha | Biomarker of peroxisomal proliferation and PPAR alpha signaling |
| UCP1 | Uncoupling protein in brown adipose tissue, PPAR gamma target | Thermogenesis and energy expenditure studies |
| IL6 | Inflammatory cytokine modulated by PPAR gamma | Links PPAR signaling to inflammation and cancer |
| TNF | Pro-inflammatory cytokine suppressed by PPAR activation | Readout of anti-inflammatory PPAR effects |
| SQSTM1 | Autophagy receptor crosstalking with PPAR signaling | Connects GO:0035357 to autophagic flux |
| MAP1LC3B | Autophagosome marker influenced by PPAR pathway | Used to monitor autophagy-PPAR crosstalk |
| PPARGC1A | Transcriptional coactivator enhancing PPAR alpha target gene expression | Regulates mitochondrial biogenesis and energy metabolism |
How Is peroxisome proliferator activated receptor signaling pathway Regulated?
The peroxisome proliferator activated receptor signaling pathway is regulated at multiple levels. Ligand availability, including endogenous fatty acids and eicosanoids, determines receptor activation. Post-translational modifications such as phosphorylation can modulate PPAR activity and cofactor recruitment. Corepressor and coactivator exchange controls the switch between repression and activation of target genes. Additionally, crosstalk with autophagy influences PPAR ligand availability and downstream metabolic homeostasis. In disease contexts, PPAR signaling is modulated by inflammatory cytokines and redox status, as seen in cancer and autoimmune thyroiditis.
peroxisome proliferator activated receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARG | Cancer chemoprevention and sperm physiology | Knockout and knock-in cell models to test agonists |
| PPARA | Hepatocarcinogenesis and lipid metabolism | Liver-specific knockout and overexpression models |
| PPARD | Pulmonary vasodilation and cancer redox signaling | Point-mutation models to dissect ligand specificity |
| RXRA | Core pathway component in metabolic disease | Conditional knockout to avoid lethality |
| SQSTM1 | Autophagy-related metabolic homeostasis | Knockout models to study PPAR-autophagy crosstalk |
PPAR signaling in cancer
Dysregulation of PPAR signaling is implicated in multiple cancers. PPAR gamma pathway targeting has been proposed for chemoprevention, with evidence that activation can inhibit carcinogenesis. PPAR alpha signaling has been linked to hepatocarcinogenesis, where its effects depend on context and ligand availability. PPAR beta/delta, reactive oxygen species, and redox signaling are targets for phytocompound-based cancer therapy, highlighting the pathway's role in oxidative stress responses.
PPAR signaling in metabolic and autoimmune disorders
PPAR signaling is central to lipid metabolism and energy homeostasis, and its dysfunction contributes to metabolic disorders. Multi-omics analysis has shown that Bailing capsule alleviates autoimmune thyroiditis by regulating the PPAR signaling pathway, linking GO:0035357 to autoimmune disease. Autophagy-PPAR crosstalk further connects the pathway to metabolic homeostasis and disease.
PPAR signaling in pulmonary and reproductive biology
PPAR beta/delta acts as an acute signaling factor in prostacyclin-induced pulmonary vasodilation, with implications for pulmonary hypertension. PPAR gamma signaling influences human sperm physiology, suggesting a role in reproductive function. These findings expand the disease relevance of GO:0035357 beyond classical metabolic tissues.
From peroxisome proliferator activated receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PPARG loss alter adipogenesis? | PPARG knockout cell line (e.g., 3T3-L1) |
| Does a PPARA point mutation affect ligand binding? | Point-mutation knock-in via CRISPR |
| Can a tagged PPARG reveal cofactor recruitment? | Tagged knock-in (e.g., GFP or HA) |
| Does PPARD overexpression drive redox signaling? | Overexpression cell model |
| Is RXRA required for PPAR target gene activation? | Conditional RXRA knockout |
| Does autophagy modulate PPAR ligand availability? | SQSTM1 or MAP1LC3B knockout with PPAR reporter |
How to Study the peroxisome proliferator activated receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify PPAR target genes and subtype-specific programs |
| ChIP-seq | PPAR-RXR DNA binding sites | Map PPREs across the genome |
| Proteomics | Protein interactions and abundance | Discover cofactors and pathway components |
| Reporter assays | PPRE-driven transcriptional activity | Screen PPAR agonists and antagonists |
| CRISPR knockout | Loss-of-function phenotypes | Test causal roles of PPAR pathway genes |
| CRISPR knock-in | Tagged or mutant protein expression | Study localization and ligand binding |
| Autophagy flux assays | Autophagic degradation activity | Assess PPAR-autophagy crosstalk |
| Multi-omics integration | Combined genomic and metabolomic data | Dissect pathway regulation in disease |
Transcriptomic profiling of PPAR target genes
RNA-seq is widely used to measure global changes in gene expression upon PPAR activation or perturbation. This method identifies PPAR response element-containing genes and reveals subtype-specific transcriptional programs. In disease models, RNA-seq can uncover pathway dysregulation, as shown in autoimmune thyroiditis studies.
Proteomic and cofactor interaction studies
Proteomics and co-immunoprecipitation can identify PPAR-interacting proteins, including coactivators and corepressors. These approaches help map the dynamic composition of the PPAR-RXR transcriptional complex. Mass spectrometry-based interactomics is valuable for understanding how ligands reshape the PPAR interactome.
Imaging and reporter assays
Fluorescent reporters and live-cell imaging allow real-time monitoring of PPAR nuclear translocation and PPRE-driven transcription. These methods are useful for screening agonists and antagonists in high-throughput formats. Imaging of autophagy markers alongside PPAR reporters can reveal crosstalk.
CRISPR-based functional genomics
CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of PPAR pathway genes. Library screening can identify modifiers of PPAR signaling at genome scale. These approaches are essential for validating drug targets and understanding disease mechanisms.
How CRISPR Can Be Used to Study GO:0035357 peroxisome proliferator activated receptor signaling pathway
Knockout
CRISPR knockout of PPAR pathway genes (e.g., PPARA, PPARG, PPARD, RXRA) creates loss-of-function models to test their causal roles in lipid metabolism, cancer, and autophagy. These models are essential for distinguishing subtype-specific functions and for validating drug targets.
Point Mutation
Point mutations introduced by CRISPR base editing or HDR can mimic disease-associated variants or alter ligand-binding residues in PPARs. Such models help dissect the molecular determinants of ligand specificity and receptor activation.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter cassettes into PPAR loci enables real-time tracking of protein localization and transcriptional activity. Knock-in of human PPAR variants into mouse models can humanize the pathway for drug testing.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can drive PPAR pathway components to supraphysiological levels, revealing gain-of-function phenotypes and downstream target gene activation. Overexpression models are particularly useful for studying PPAR beta/delta in pulmonary vasodilation and redox signaling.
How EDITGENE Supports peroxisome proliferator activated receptor signaling pathway Research
Researchers studying peroxisome proliferator activated receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway output, disease progression, or drug response. EDITGENE provides publication-ready CRISPR cell models and screening services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for peroxisome proliferator activated receptor signaling pathway research.
Frequently Asked Questions About peroxisome proliferator activated receptor signaling pathway
What is GO:0035357?
GO:0035357 is the Gene Ontology term for the peroxisome proliferator activated receptor signaling pathway, a nuclear receptor-mediated pathway initiated by ligand binding to PPAR alpha, beta/delta, or gamma and ending with regulation of downstream cellular processes such as transcription.
What genes are involved in peroxisome proliferator activated receptor signaling pathway?
Key genes include PPARA, PPARD, PPARG, RXRA, RXRB, and cofactors such as NCOA1, NCOA2, NCOR1, and NCOR2.
What does PPAR signaling do in the cell?
PPAR signaling regulates lipid metabolism, energy homeostasis, autophagy, and gene transcription in response to fatty acid-derived ligands.
How is PPAR signaling linked to cancer?
PPAR gamma targeting is explored for chemoprevention, PPAR alpha is implicated in hepatocarcinogenesis, and PPAR beta/delta is linked to redox signaling in cancer.
What diseases involve PPAR signaling?
PPAR signaling is implicated in cancer, metabolic disorders, autoimmune thyroiditis, pulmonary vasodilation defects, and reproductive biology.
What are the three PPAR subtypes?
The three subtypes are PPAR alpha (NR1C1), PPAR beta/delta (NR1C2), and PPAR gamma (NR1C3), each with distinct tissue distribution and functions.
How does PPAR signaling regulate autophagy?
PPAR signaling crosstalks with autophagy in a molecular ballet that controls lipid metabolism and homeostasis.
What methods are used to study PPAR signaling?
Common methods include RNA-seq, ChIP-seq, proteomics, reporter assays, and CRISPR knockout or knock-in models.
Can CRISPR be used to study PPAR pathway genes?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models are widely used to dissect PPAR pathway causality and drug response.
What drugs target PPAR signaling?
Fibrates activate PPAR alpha to lower lipids, and thiazolidinediones activate PPAR gamma to improve insulin sensitivity.
Conclusion
GO:0035357 (peroxisome proliferator activated receptor signaling pathway) is a fundamental nuclear receptor signaling cascade that connects lipid-derived ligands to transcriptional programs controlling metabolism, autophagy, and cell fate. Its three subtypes, PPAR alpha, beta/delta, and gamma, mediate distinct and overlapping functions that are dysregulated in cancer, metabolic disease, autoimmune thyroiditis, and pulmonary disorders. Understanding the molecular steps of this pathway is essential for developing subtype-selective therapeutics and for interpreting disease-associated variants. CRISPR-based models, combined with multi-omics and imaging approaches, provide powerful tools to dissect PPAR signaling causality and to accelerate translational research.
References
- 1. Wagner N et al.. 2020. The Role of PPARs in Disease.. Cells 9(11) PMID: 33126411
- 2. Kaur C et al.. 2024. Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy.. Antioxid Redox Signal 41(4-6):342-395 PMID: 38299535
- 3. Kiani P et al.. 2025. Autophagy and the peroxisome proliferator-activated receptor signaling pathway: A molecular ballet in lipid metabolism and homeostasis.. Mol Cell Biochem 480(6):3477-3499 PMID: 39891864
- 4. Misra P et al.. 2013. Peroxisome proliferator-activated receptor-α signaling in hepatocarcinogenesis.. Subcell Biochem 69:77-99 PMID: 23821144
- 5. Liu LL et al.. 2015. Peroxisome proliferator-activated receptor gamma signaling in human sperm physiology.. Asian J Androl 17(6):942-7 PMID: 25851655
- 6. Li Y et al.. 2012. Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.. Am J Respir Cell Mol Biol 46(3):372-9 PMID: 22021335
- 7. Qixin W et al.. 2024. Bailing capsule alleviates autoimmune thyroiditis regulating peroxisome proliferator-activated receptor signaling pathway: a multi-omics analysis.. J Tradit Chin Med 44(6):1217-1226 PMID: 39617707
- 8. Ondrey F. 2009. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.. Clin Cancer Res 15(1):2-8 PMID: 19118026
